Skip to main content
SpringerLink
Log in

Use of Corticosteroids in Kidney Transplantion

  • Chapter
Current and Future Immunosuppressive Therapies Following Transplantation

Abstract

Corticosteroids have played a key role in the evolution of successful organ transplantation. Azathioprine was actually the first immunosuppressive agent used for human kidney transplant recipients in the late 1950s. However, in 1951, Billingham et al demonstrated that steroids prevented rejection and prolonged the survival of skin grafts in rabbits [1]. The effectiveness of large doses of corticosteroids in suppressing and reversing human renal allograft rejection was first reported in the early 1960s [2],[3]. Thereafter, combination of azathioprine and steroids became the conventional maintenance immunosuppression regimen in organ transplantation and remained so for almost two decades.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin homografts in rabbits. Br Med J 1951; 1: 4716.

    Article  Google Scholar 

  2. Starzl TE, Marchioro TL, Waddel WR. The reversal of rejection in renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385–395.

    PubMed  CAS  Google Scholar 

  3. Goodwin WE, Kaufman JJ, Mims MM, et al. Human renal transplantation. I. Clinical experiences with six cases of renal homotransplantation. J Urol 1963; 89: 13–17.

    PubMed  CAS  Google Scholar 

  4. Siegel RR, Luke RG, Hellebusch AA. Reduction of toxicity of corticosteroid therapy after renal transplantation. Am J Med 1972; 53: 159–169.

    Article  PubMed  CAS  Google Scholar 

  5. Chan L, French ME, Beare J, Oliver DO, Morris PJ. Prospective trial of high-dose versus low-dose prednisolone in renal transplant patients. Transplant Proc 1980; 12: 323–326.

    PubMed  CAS  Google Scholar 

  6. Buckels JA, Mackintosh P, Barnes AD. Controlled trial of low versus high dose oral steroid therapy in 100 cadaveric renal transplants. Proc EDTA 1981; 18: 394–399.

    CAS  Google Scholar 

  7. Park GD, Bartucci M, Smith MC. High-versus low-dose methylprednisolone for acute rejection episodes in renal transplantation. Nephron 1984; 36: 80–83.

    Article  PubMed  CAS  Google Scholar 

  8. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57: 979–989.

    PubMed  CAS  Google Scholar 

  9. Fauci AS. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1975; 46: 235–240.

    PubMed  CAS  Google Scholar 

  10. Hollenberg SM, Evans RM. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 1988; 55: 899–906.

    Article  PubMed  CAS  Google Scholar 

  11. Guigere V, Hollenberg SM, Rosenfeld MG, Evans RM. Functional domains of the human glucocorticoid receptor. Cell 1986; 46: 645–652.

    Article  Google Scholar 

  12. Almawi WY, Hadro ET, Strom TB. Evidence that giucocorticosteroid-mediated immunosuppressive effects do not involve altering second messenger function. Transplantation 1991; 52: 133–140.

    Article  PubMed  CAS  Google Scholar 

  13. Vacca A, Felli MP, Farina AR, et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992; 175: 637–646.

    Article  PubMed  CAS  Google Scholar 

  14. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436–441.

    Article  PubMed  CAS  Google Scholar 

  15. Barnes PJ, Karin M. Nuclear factor-KB — a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071.

    Article  PubMed  CAS  Google Scholar 

  16. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752–756.

    Article  PubMed  CAS  Google Scholar 

  17. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995; 15: 943–953.

    PubMed  CAS  Google Scholar 

  18. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286.

    Article  PubMed  CAS  Google Scholar 

  19. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139: 4129–4134.

    PubMed  CAS  Google Scholar 

  20. Kern JA, Lamb RJ, Reed JC, et al. Dexamethasone inhibition of interleukin 1 beta production by human monocytes: posttranscriptional mechanisms. J Clin Invest 1988; 81: 237–244.

    Article  PubMed  CAS  Google Scholar 

  21. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocorticoids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49: 183–185.

    Article  PubMed  CAS  Google Scholar 

  22. Culpepper, J.A, Lee F. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol 1985; 135: 3191–3197.

    PubMed  CAS  Google Scholar 

  23. Gessani S, McCandless S, Baglioni C. The glucocorticoid dexamethasone inhibits synthesis of interferon by decreasing the level of its mRNA. J Biol Chem 1988; 263: 7454–7457.

    PubMed  CAS  Google Scholar 

  24. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and gamma interferon messenger RNA. J Immunology 1984; 133: 273–276.

    CAS  Google Scholar 

  25. Waage A, Baake O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988; 63: 299–302.

    PubMed  CAS  Google Scholar 

  26. Granelli-Piperno A, Nolan P, Inaba K, et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites in the interlekin 2 promoter. J Exp Med 1990; 172: 1869–1872.

    Article  PubMed  CAS  Google Scholar 

  27. Shen V, Cheng SL, Kohler NG, et al. Characterization and hormonal modulation of IL-1 binding in neonatal mouse osteoblast-like cells. J Bone Miner Res 1990; 5: 507–515.

    Article  PubMed  CAS  Google Scholar 

  28. Schooltink H, Schmitz-Van der Leur H, Heinrich PC, et al. Upregulation of the interleukin-6-signal transducing protein (gpl30) by intertekin-6 and dexamethasone in HepG2 cells. FBS Lett 1992; 297: 263–265.

    Article  CAS  Google Scholar 

  29. Strickland RW, Wahl LM, Finbloom DS. Corticosteroids enhance the binding of recombinant interferon gamma to cultured monocytes. J Immunology 1986; 137: 1577–1580.

    CAS  Google Scholar 

  30. Haynes RC Adrenocortical steroids and their synthetic analogs. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics. New York; Pergamon Press, 1990: 1431.

    Google Scholar 

  31. Snyers L, De Wit L, Content J. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci USA 1990; 87: 2838.

    Article  PubMed  CAS  Google Scholar 

  32. Tornatore KM, Reed KA, Venuto RC Assessment of methylprednisolone pharmacokinetics and Cortisol response during early and chronic postrenal-transplant periods. Transplantation 1995; 60: 1607–1611.

    Article  PubMed  CAS  Google Scholar 

  33. Cimminelli AM, Reed KA, Farooqui M, Venuto RC, Tornatore KM. Glucocorticoid pharmacokinetics in postmenopausal renal transplant recipients. Pharmacother (abstract) 1998

    Google Scholar 

  34. Tornatore KM, Biocevich D, Reed KA, Tousley K, Singh P, Venuto RC. Methylprednisolone pharmacokinetics, Cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 1995; 59: 729–736.

    Article  PubMed  CAS  Google Scholar 

  35. Tornatore KM, Reed KA, Venuto RC Racial differences in pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacother 1993; 13: 481–486.

    CAS  Google Scholar 

  36. Tornatore KM, Reed K, Walshe JJ, Venuto RC Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Pharmacother 1994; 14: 111–118.

    CAS  Google Scholar 

  37. Bell PRF, Briggs JD, Caiman KC, et al. Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone. Lancet 1971; 1: 876–880.

    Article  PubMed  CAS  Google Scholar 

  38. Alarcon-Zurita A, Ladefoged J. Treatment of acute allograft rejection with high doses of corticosteroids. Kidney Int 1976; 9:351354.

    Article  Google Scholar 

  39. Mussche MM, Ringoir SMG, Lamiere NN. High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 1976; 16:287–291.

    Article  PubMed  CAS  Google Scholar 

  40. Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. Lancet 1978; 1:117–118.

    Article  PubMed  CAS  Google Scholar 

  41. Orta-Sibu N, Chantier C, Bewick M, Hancock G. Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J 1982; 285: 255–260.

    Article  Google Scholar 

  42. Woods JE, Anderson CF, DeWeerd JH, et al. High-dosage intravenously administered methylprednisolone in renal transplantation. A preliminary report. JAMA 1973; 223: 896–899.

    Article  PubMed  CAS  Google Scholar 

  43. Webel ML, Ritts RE, Taswell HF, Donadio JV, Woods JE. Celular immunity after intravenous administration of methylprednisolone. J Lab Clin Med 1974; 83: 383–392.

    PubMed  CAS  Google Scholar 

  44. Fan PT, Yu DTY, Targoff C, Bluestone R. Effect of corticosteroids on the human immune response. Suppression of mitogen-induced lymphocyte proliferation by “pulse” methylprednisolone. Transplantation 1978; 26: 266–267.

    Article  PubMed  CAS  Google Scholar 

  45. Kauffman HM, Stromstad SA, Sampson D, Stawicki AT. Randomized steroid therapy of human kidney transplant rejection. Transplant Proc 1979; 11: 36–38.

    PubMed  Google Scholar 

  46. Cosimi AB. The clinical value of antilymphocyte antibodies. Transplant Proc 1981; 15: 462–468.

    Google Scholar 

  47. Shield CF, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J, Russell PS. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979; 28: 461–464.

    PubMed  Google Scholar 

  48. Filo RS, Smith EJ, Leapman SB. Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 1980; 30: 445–449.

    Article  PubMed  CAS  Google Scholar 

  49. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337–341.

    Article  Google Scholar 

  50. Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM. OKT3 for primary therapy of first rejection episode in kidney transplants. Transplantation 1993; 55: 1023–1029.

    Article  PubMed  CAS  Google Scholar 

  51. Kamath S, Dean D, Peddi VR, et al. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection. Transplantation 1997; 64: 1428–1432.

    Article  PubMed  CAS  Google Scholar 

  52. Kauffman HM, Sampson D, Fox PS, Stawicki AT. High dose (bolus) intravenous methylprednisolone at the time of kidney homotransplantation. Ann Surg 1977; 186: 631–634.

    Article  PubMed  CAS  Google Scholar 

  53. McGeown MG, Douglas JF, Brown WA et al. Low dose steroid from the day following renal transplantation. Proc EDTA 1979; 16: 395–400.

    CAS  Google Scholar 

  54. Ponticelli C, De Vecchi AF, Tarantino A, et al. A search for optimizing corticosteroid administration to renal transplant patients. Kidney Int 1983; 23(suppl 14): S85–S89.

    Google Scholar 

  55. Hayry P, Ahonen J, Kock B, et al. Glucocorticoids in renal transplantation. II. Impact of high-versus low-dose postoperative methylprednisolone administration on graft survival and on the frequency and type of complications. Scand J Immunol 1984; 19: 211–218.

    Article  PubMed  CAS  Google Scholar 

  56. D’Apice AJF, Becker GJ, Kincaid-Smith P, et al. A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 1984; 37: 373–377.

    Article  PubMed  Google Scholar 

  57. Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE. Long-term alternate day steroid therapy in renal transplantation. Transplantation 1982; 34: 78–82.

    Article  PubMed  CAS  Google Scholar 

  58. De Vecchi A, Cantaluppi A, Montagnino G, Tarantino A, Maestri O, Ponticelli C. Long-term comparison between single-morning daily and alternate-day steroid treatment in cadaver kidney recipients. Transplant Proc 1980; 12: 327–330.

    PubMed  Google Scholar 

  59. Diethelm AG, Sterling WA, Hartley MW, Morgan JM. Alternate-day prednisone therapy in recipients of renal allografts. Arch Surg 1976; 111: 867–870.

    Article  PubMed  CAS  Google Scholar 

  60. Bell MJ, Martin LW, Gonzales LL, McEnery PT, West C.D. Alternate-day singledose prednisone therapy: a method of reducing steroid toxicity. J Pediatric Surg 1972; 7: 223–229.

    Article  CAS  Google Scholar 

  61. Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG. Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol 1976; 5: 123–127.

    PubMed  CAS  Google Scholar 

  62. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int 1982; 22: 42–47.

    Article  PubMed  CAS  Google Scholar 

  63. Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979; 91: 554–559.

    PubMed  CAS  Google Scholar 

  64. Drukker A, Turner C, Start K, et al. Hyperlipidemia after renal transplantation in children on alternate day corticosteroid therapy. Clin Nephrol 1986; 26: 140–145.

    PubMed  CAS  Google Scholar 

  65. McEnery PT, Gonzalez LL, Martin LW, West CD. Growth and development of children with renal transplants. Use of alternate-day steroid therapy. J Pediatr 1973; 83: 806–814.

    Article  PubMed  CAS  Google Scholar 

  66. Feldhoff C, Goldman AI, Najarian JS, Mauer SM. A comparison of alternate day and daily steroid therapy in children following renal transplantation. Int J Pediatr Nephrol 1984; 5: 11–14.

    PubMed  CAS  Google Scholar 

  67. Hricik DE, Lautman J, Bartucci MR, Moir EJ Mayes JT, Schulak JA. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232–1235.

    Article  PubMed  CAS  Google Scholar 

  68. Popovtzer MM, Pinnggera W, Katx FH, et al. Variations in arterial blood pressure after kidney transplantation. Relation to renal function, plasma renin activity, and the dose of prednisone. Circulation 1973; 47: 1297–1305.

    Article  PubMed  CAS  Google Scholar 

  69. Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med 1988; 85: 131–133.

    Article  PubMed  CAS  Google Scholar 

  70. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on post-transplant hypercholesterolemia. Am J Kidney Dis 1991; 18: 353–358.

    PubMed  CAS  Google Scholar 

  71. Kasiske BL, Tororice KL, Heim-Duthoy KL, Awni WM, Rao KV. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17: 700–707.

    PubMed  CAS  Google Scholar 

  72. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11–17.

    PubMed  CAS  Google Scholar 

  73. Mejia G, Arbelaez M, Henao JE, Arango JL, Garcia A. Cyclosporine-associated diabetes mellitus in renal transplants. Clin Transplant 1989; 3: 260–264.

    Google Scholar 

  74. Dlugosz BA, Bretan PN, Novick AC, et al. Causes of death in kidney transplant recipients: 1970 to present. Transplant Proc 1989; 21: 2168–2170.

    PubMed  CAS  Google Scholar 

  75. Hill MN, Grossman RA, Feldman HI, Hurwitz S, Dafoe DC. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991; 17: 512–518.

    PubMed  CAS  Google Scholar 

  76. Naik RB, Abdeen H, English J, Chakraborty J, Slapak M, Lee HA. Prednisolone withdrawal after 2 years in renal transplant patients receiving only this form of immunosuppression. Transplant Proc 1979; 11: 39–41.

    PubMed  CAS  Google Scholar 

  77. Steinman TI, Zimmerman CE, Monaco AP, et al. Steroids can be stopped in kidney transplant recipients. Transplant Proc 1981; 13:323–324.

    PubMed  CAS  Google Scholar 

  78. Thaysen JH, Lokegaard H. Permanent withdrawal of prednisone in kidney transplantation. Scand J Urol Nephrol 1977; 42(suppl): 198–203.

    Google Scholar 

  79. First MR, Munda R, Kant KS, Fidler JP, Alexander JW. Steroid withdrawal following HLA-identical related donor transplantation. Transplant Proc 1981; 13: 319–321.

    PubMed  CAS  Google Scholar 

  80. European Multicentre Trial. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet 1982; 2: 57–60.

    Google Scholar 

  81. Griffin PJA, Gomes Da Costa CA, Salaman JR. A controlled trial of steroids in cyclosporine-treated renal transplant recipients. Transplantation 1987; 43: 505–508.

    Article  PubMed  CAS  Google Scholar 

  82. MacDonald AS, Daloze P, Dandavino R, et al. A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Transplant Proc 1987; 19: 1865–1867.

    PubMed  CAS  Google Scholar 

  83. Johnson RWG, Mallick NP, Bakran A, et al. A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Transplant Proc 1989; 21: 1581–1582.

    PubMed  CAS  Google Scholar 

  84. Albert FW, Schmidt U. Cyclosporine therapy with or without steroids in cadaveric kidney transplantation — a prospective randomized one-center study. Transplant Proc 1985; 17: 2669–2670.

    Google Scholar 

  85. Thiel G, Harder F, Loertscher R, et al. Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Transplant Proc 1984; 16: 1187–X.

    PubMed  CAS  Google Scholar 

  86. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53–57.

    Article  PubMed  CAS  Google Scholar 

  87. Ponticelli C, Tarantino A, Montagnino G. Controlled trials with cyclosporine in kidney transplantation. Transplant Proc 1994; 26: 2490–2492.

    PubMed  CAS  Google Scholar 

  88. Bry W, Warvariv V, Bohannon L, et al. Cadaveric renal transplant without prophylactic prednisone therapy. Transplant Proc 1991; 23: 994–996.

    PubMed  CAS  Google Scholar 

  89. Reisman L, Lieberman KV, Burrows L, et al. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76–80.

    Article  PubMed  CAS  Google Scholar 

  90. Klare B, Strom TM, Hahn H, et al. Remarkable long-term prognosis and excellent growth in kidney-transplant children under cyclosporine monotherapy. Transplant Proc 1991; 23: 1013–1017.

    PubMed  CAS  Google Scholar 

  91. Tejani A, Butt KMH, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation 1989; 47: 229–233.

    Article  PubMed  CAS  Google Scholar 

  92. David-Neto E, Vilares S, Lando V, et al. Conversion from azathioprine/prednisone to azathioprine/cyclosporin promotes catch-up growth in pediatric renal allograft recipients. Clin Transplant 1990; 4: 229–234.

    Google Scholar 

  93. Wolpaw T, Deal CL, Fleming-Brooks S, et al. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58: 1186–1189.

    PubMed  CAS  Google Scholar 

  94. Ingulli E, Tejani A, Markeil M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children post-transplantation in the cyclosporine era. Transplantation 1993; 55: 102–110.

    Article  Google Scholar 

  95. Kupin W, Venkat KK, Oh OK, et al. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53–57

    Article  PubMed  CAS  Google Scholar 

  96. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23: 1363–1364.

    PubMed  CAS  Google Scholar 

  97. Hricik DE, Lautman J, Bartucci MR, et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232–1235.

    Article  PubMed  CAS  Google Scholar 

  98. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on post-transplant hypercholesterolemia. Am J Kidney Dis 1991; 28: 353–358.

    Google Scholar 

  99. Hricik DE, Bartucci, Mayes JT, et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868–871.

    Article  PubMed  CAS  Google Scholar 

  100. Hariharan S, Schroeder TJ, Weiskittel P, et al. Prednisone withdrawal in HLA identical, one haplotype matched live related donor and cadaver renal transplant recipients. Kidney Int 1993; (suppl43):S30–S35.

    Google Scholar 

  101. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. 1991; 51: 374–377.

    CAS  Google Scholar 

  102. Fabrega AJ, Cohan J, Meslar P, et al. Effects of steroid withdrawal on long-term renal allograft recipients with post transplantation diabetes mellitus. Surgery 1994; 116: 792–797.

    PubMed  CAS  Google Scholar 

  103. Fabrega AJ, Meslar P, Cohan J, et al. Long-term (24 month) follow-up of steroid withdrawal in renal allograft recipients with post-transplant diabetes mellitus. Transplantation 1995; 60: 1612–1614.

    PubMed  CAS  Google Scholar 

  104. Schulak JA, Mayes JT, Moritz CE, et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant recipients. Transplantation 1990; 49: 327–332.

    Article  PubMed  CAS  Google Scholar 

  105. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal allograft patients treated with cyclosporine. Transplant Proc 1988; 20(Suppl 3): 121–125.

    PubMed  CAS  Google Scholar 

  106. Ratcliffe PJ, Firth JD, Higgins RM, et al. Randomized controlled trial of complete steroid withdrawal in renal transplant patients receiving triple immunosuppression. Transplant Proc 1993; 25: 590.

    PubMed  CAS  Google Scholar 

  107. Sinclair NR, Canadian Multicenter Transplant Study Group. Low dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147: 645–655.

    CAS  Google Scholar 

  108. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61: 1038–1046.

    Article  PubMed  CAS  Google Scholar 

  109. Flechner SM, Kerman RH, Van Buren CT, et al. The use of cyclosporine in living-related renal transplantation: donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38: 685–690.

    Article  PubMed  CAS  Google Scholar 

  110. Cristinelli C, Brunori G, Sett G, et al. Withdrawal of methylprednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc 1987; 19: 2021–2023.

    PubMed  CAS  Google Scholar 

  111. O’Connell P, D’Apice A, Walker R, et al. Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone. Transplant Proc 1988; 20: 11–13.

    PubMed  Google Scholar 

  112. Walker RG, D’Apice AJF, Powell HR, et al. Triple low-dose immunosuppression with cessation of steroids in pediatric renal transplantation. Transplant Proc 1988; 20: 7–10.

    PubMed  CAS  Google Scholar 

  113. Gulanikar AC, Belitsy P, MacDonald AS. Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990–991.

    PubMed  CAS  Google Scholar 

  114. Hricik DE, O’Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300–1305.

    PubMed  CAS  Google Scholar 

  115. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 1988; 45: 323–328.

    Article  PubMed  CAS  Google Scholar 

  116. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation — clinical predictors of outcome. Transplantation 1992; 53: 41–45.

    Article  PubMed  CAS  Google Scholar 

  117. Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4(Suppl): S10–S16.

    PubMed  CAS  Google Scholar 

  118. Hricik DE, Seliga RM, Fleming-Brooks S, et al. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Clin Transplant 1995; 9: 419–423.

    PubMed  CAS  Google Scholar 

  119. Tarantino A, Montagnino G, Ponticelli C. Corticosteroids in kidney transplant recipients: safety issues and timing of discontinuation. Drug Saf 1995; 13: 145–156.

    Article  PubMed  CAS  Google Scholar 

  120. Ratcliffe PJ, Dudley CRK, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643–648.

    Article  PubMed  CAS  Google Scholar 

  121. Hollander AMJ, Hene RJ, Hermans J, Van Es LA, Van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294–301.

    PubMed  CAS  Google Scholar 

  122. Ghandour FZ, Knauss TC, Schulak JA, et al. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clin Transplant 1997; 11: 395–398.

    PubMed  CAS  Google Scholar 

  123. Isoniemi HM, Krogerus L, von Willebrand E, et al. Histopathologic findings in well-functioning, long-term allografts. Kidney Int 1992; 41: 155–160.

    Article  PubMed  CAS  Google Scholar 

  124. Offerman G, Schwarz A, Krause PH. Long-term effects of steroid withdrawal in kidney transplantation. Transplant Int 1993; 6: 290–292.

    Article  Google Scholar 

  125. Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443–446.

    Article  PubMed  CAS  Google Scholar 

  126. Shapiro R, Jordan ML, Scantlebury VP, et al. Outcomes after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998; 30: 1375–1377.

    Article  PubMed  CAS  Google Scholar 

  127. Woodle ES, Buell J, Siegel C, Kulkarni S, Kopelan A, Grewal HP. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. Transplant Proc 1999; 31(Suppl):84S–85S.

    Article  PubMed  CAS  Google Scholar 

  128. Grinyo JM, Gil-Vernet S, Seron D, et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997; 63: 1688–1690.

    Article  PubMed  CAS  Google Scholar 

  129. Kupin W, Venkat KK, Goggins M. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients. Transplant Proc 1999; 31:1131–1132.

    Article  PubMed  CAS  Google Scholar 

  130. Lebranchu Y for the M55002 Study Group. Comparison of two corticosteroid regimens in combination with Cellcept and cyclosporine A for prevention of acute allograft rejection: 12-month results of a double-blind, randomized, multicenter study. Transplant Proc 1999; 21:249–251.

    Article  Google Scholar 

  131. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil — a prospective randomized study. Transplantation 1999; 68: 1865–1874.

    Article  Google Scholar 

  132. Kahan BD. Am Soc Transplant Phys. 1998; p243

    Google Scholar 

Download references

Authors
  1. Donald E. Hricik
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harvard Medical School, Boston, MA, USA

    Mohamed H. Sayegh

  2. Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    Giuseppe Remuzzi

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Kluwer Academic Publishers

About this chapter

Cite this chapter

Hricik, D.E. (2001). Use of Corticosteroids in Kidney Transplantion. In: Sayegh, M.H., Remuzzi, G. (eds) Current and Future Immunosuppressive Therapies Following Transplantation. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-1005-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-1005-4_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3876-8

  • Online ISBN: 978-94-010-1005-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation